Analysis shows no extra risks in infliximab for Crohn's

10/15/2008 | MedPage Today (free registration)

An analysis of the 6,273-patient Crohn's Therapy Resource, Evaluation and Assessment Tool, or TREAT, registry found taking infliximab is not any riskier for Crohn's patients than other immunomodulating drugs. The researchers did find the risk of death increased by 86% among prednisone users and doubled for patients given narcotic analgesics.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN